Johnathon David Anderson, Ph.D.

Associate Professor in Residence



Regenerative Medicine

Drug Discovery



Locations and Contact

UC Davis Institute for Regenerative Cures (IRC)

UC Davis Institute for Regenerative Cures (IRC)
2921 Stockton Blvd.
Sacramento, CA 95817

Get Directions

Glassrock Building

Glassrock Building
2521 Stockton Blvd.
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Research/Academic Interests

Dr. Anderson's research focuses on how tumor cells communicate with the cells that surround them in the tumor bed using extracellular vesicles called exosomes. He investigates how cancer cells modify the function of stromal and immune cells in the tumor bed to make them more supportive of tumor progression. This work ultimately aims to develop new immunotherapies for the treatment of head and neck cancer. 


Head and Neck Surgery

Center/Program Affiliation

Institute for Regenerative Cures
UC Davis Comprehensive Cancer Center

Undergraduate School

B.S., Genetics, UC Davis, Davis CA 2011

Other School

Ph.D., Genetics, UC Davis, Institute for Regenerative Cures, Davis CA 2015

Other School

Postdoc, Regenerative Medicine, UC Davis, Institute for Regenerative Cures, Sacramento CA 2017


Pharmacology, Oxford University, Oxford, UK 2018


Cardiovascular Research, UC Davis Medical Center, Sacramento CA 2015-2017

Dickenson Fellowship, 2017

ASNTR 2016 Research Award, 2017

NIH T32 Cardiovascular Medicine Fellowship 2014, 2015, 2016

National Science Foundation GROW, 2013

Phi Sigma Biological Sciences Honor Society Fellow, 2013

Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussolati B, Carter DRF, Dominici M, Falcón-Pérez JM, Gimona M, Hill AF, Hoffman AM, de Kleijn D, Levine BL, Lim R, Lötvall J, Mitsialis SA, Monguió-Tortajada M, Muraca M, Nieuwland R, Nowocin A, O'Driscoll L, Ortiz LA, Phinney DG, Reischl I, Rohde E, Sanzenbacher R, Théry C, Toh WS, Witwer KW, Lim SK, Giebel B. ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19. Cytotherapy. 2020 May 16. doi:10.1016/j.jcyt.2020.05.002. PMID:32425691.

Halmai JANM, Deng P, Gonzalez CE, Coggins NB, Cameron D, Carter JL, Buchanan FKB, Waldo JJ, Lock SR, Anderson JD, O'Geen H, Segal DJ, Nolta J, Fink KD. Artificial escape from XCI by DNA methylation editing of the CDKL5 gene. Nucleic Acids Res. 2020 Mar 18;48(5):2372-2387. doi:10.1093/nar/gkz1214. PMID:31925439.

Clayton SM, Archard JA, Wagner J, Farwell DG, Bewley AF, Beliveau A, Birkeland A, Rao S, Abouyared M, Belafsky PC, Anderson JD. Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. Stem Cells Dev. 2020 Mar 15;29(6):327-335. doi:10.1089/scd.2019.0197. Epub 2020 Jan 30. PMID:31856674.

Elahi FM, Farwell DG, Nolta JA, Anderson JD. Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem Cells. 2020 Jan;38(1):15-21. doi: 10.1002/stem.3061. Epub 2019 Oct 1. PMID:31381842.

Showalter MR, Wancewicz B, Fiehn O, Archard JA, Clayton S, Wagner J, Deng P, Halmai J, Fink KD, Bauer G, Fury B, Perotti NH, Apperson M, Butters J, Belafsky P, Farwell G, Kuhn M, Nolta JA, Anderson JD. Primed mesenchymal stem cells package exosomes with metabolites associated with immunomodulation. Biochem Biophys Res Commun. 2019 May 14;512(4):729-735. doi:10.1016/j.bbrc.2019.03.119. Epub 2019 Mar 26. PMID:30926165.

Yuan O, Lin C, Wagner J, Archard JA, Deng P, Halmai J, Bauer G, Fink KD, Fury B, Perotti NH, Walker JE, Pollock K, Apperson M, Butters J, Belafsky P, Farwell DG, Kuhn M, Nolta J, Anderson JD. Exosomes Derived from Human Primed Mesenchymal Stem Cells Induce Mitosis and Potentiate Growth Factor Secretion. Stem Cells Dev. 2019 Mar 15;28(6):398-409. doi:10.1089/scd.2018.0200. Epub 2019 Feb 26. PMID:30638129.

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018 Nov 23;7(1):1535750. doi:10.1080/20013078.2018.1535750. eCollection 2018. PMID:30637094.

Moisseiev E, Anderson JD, Oltjen S, Goswami M, Zawadzki RJ, Nolta JA, Park SS. Protective Effect of Intravitreal Administration of Exosomes Derived from Mesenchymal Stem Cells on Retinal Ischemia. Curr Eye Res. 2017 Oct;42(10):1358-1367. doi:10.1080/02713683.2017.1319491. Epub 2017 Jun 21. PMID:28636406.

Park SS, Moisseiev E, Bauer G, Anderson JD, Grant MB, Zam A, Zawadzki RJ, Werner JS, Nolta JA. Advances in bone marrow stem cell therapy for retinal dysfunction. Prog Retin Eye Res. 2017 Jan;56:148-165. doi:10.1016/j.preteyeres.2016.10.002. Epub 2016 Oct 23. PMID:27784628.

Anderson JD, Johansson HJ, Graham CS, Vesterlund M, Pham MT, Bramlett CS, Montgomery EN, Mellema MS, Bardini RL, Contreras Z, Hoon M, Bauer G, Fink KD, Fury B, Hendrix KJ, Chedin F, El-Andaloussi S, Hwang B, Mulligan MS, Lehtiö J, Nolta JA. Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor-KappaB Signaling. Stem Cells. 2016 Mar;34(3):601-13. doi:10.1002/stem.2298. Epub 2016 Feb 19. PMID:26782178.

Johnathon D. Anderson, Ph.D.